Latest Addex Pharma Ord (ADDXF) Headlines
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alcohol Addiction - Pipeline Review, H2 2013
M2 - Thu Dec 05, 2:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/gr5s82/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H2 2013" report to their offering. 'Alcohol Addiction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Alcohol Addiction. - A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alcohol Addiction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Eli Lilly and Company Tekmira Pharmaceuticals Corp. Pfizer Inc. Sun Pharmaceutical Industries Limited Addex Pharmaceuticals Curemark, LLC Omeros Corporation Heptares Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/gr..._addiction About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013
M2 - Mon Nov 18, 3:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqp3kf/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013" report to their offering. 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Scope - A snapshot of the global therapeutic scenario for Post-Traumatic Stress Disorder (PTSD). - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Nanotherapeutics, Inc. Neurocrine Biosciences, Inc. Addex Pharmaceuticals Neuralstem, Inc. Catalyst Pharmaceutical Partners, Inc. Humanetics Corporation NeuroNascent, Inc. Azevan Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/zq...ttraumatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dyskinesia - Pipeline Review, H2 2013
M2 - Thu Oct 10, 2:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/893c4b/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H2 2013" report to their offering. 'Dyskinesia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dyskinesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyskinesia. Scope - A snapshot of the global therapeutic scenario for Dyskinesia. - A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dyskinesia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Dyskinesia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned XenoPort, Inc. Novartis AG Cubist Pharmaceuticals, Inc. Addex Pharmaceuticals AVANIR Pharmaceuticals Catalyst Pharmaceutical Partners, Inc. Repligen Corporation Neurim Pharmaceuticals (1991) Ltd. Santhera Pharmaceuticals Holding AG Asubio Pharmaceuticals, Inc. Upsher-Smith Laboratories, Inc. PsychoGenics, Inc. Adamas Pharmaceuticals, Inc. Targacept, Inc. Heptares Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/893c4b/dyskinesia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Endometriosis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9zxrdh/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2013" report to their offering. 'Endometriosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. Scope - A snapshot of the global therapeutic scenario for Endometriosis. - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Endometriosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Euroscreen S.A. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Astellas Pharma Inc. Kissei Pharmaceutical Co., Ltd. Bayer AG Addex Pharmaceuticals Evotec Aktiengesellschaft ValiRx Plc Repros Therapeutics Inc. DONGKOOK Pharmaceutical Co., Ltd. Camurus AB Lipicard Technologies Limited Orphagen Pharmaceuticals, Inc. Quatrx Pharmaceutical Company Peptron, Inc. PregLem SA EndoCeutics, Inc. Isifer AB For more information visit http://www.researchandmarkets.com/research/9z...ometriosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Incontinence - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gnq99s/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2013" report to their offering. 'Urinary Incontinence - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. Scope - A snapshot of the global therapeutic scenario for Urinary Incontinence. - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Cook Medical Incorporated Allergan, Inc. Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation Recordati S.p.A. Addex Pharmaceuticals Evotec Aktiengesellschaft Plethora Solutions Holdings plc Melior Discovery, Inc. Fate Therapeutics, Inc. Celogos Sinil Pharma Ltd. Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/gnq99s/urinary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Spasticity Pipeline Review Report - Latest 2013 Edition
M2 - Wed Sep 04, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrtp7w/spasticity) has announced the addition of the "Spasticity - Pipeline Review, H2 2013" report to their offering. 'Spasticity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. Scope - A snapshot of the global therapeutic scenario for Spasticity. - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spasticity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Spasticity Therapeutics Development - Ipsen S.A. - Novartis AG - Merz GmbH & Co. KGaA - Sun Pharmaceutical Industries Limited - Addex Pharmaceuticals - GW Pharmaceuticals plc - Sanochemia Pharmazeutika AG - Raptor Pharmaceuticals Corp. - Osmotica Pharmaceutical Corp. - Intec Pharma ltd. - Concert Pharmaceuticals, Inc. Drug Profiles - nabiximols - arbaclofen - NGX-426 - tezampanel - abobotulinumtoxinA - onabotulinumtoxinA - BGG-492 - ADX-71441 - SUN-09 - CTP-354 - baclofen ER - onabotulinumtoxinA For more information visit http://www.researchandmarkets.com/research/zrtp7w/spasticity
Gouty Arthritis (Gout) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6xk6h/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2013" report to their offering. 'Gouty Arthritis (Gout) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). Scope - A snapshot of the global therapeutic scenario for Gouty Arthritis (Gout). - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Teijin Pharma Limited Novartis AG Kissei Pharmaceutical Co., Ltd. Addex Pharmaceuticals BioCryst Pharmaceuticals, Inc. SANWA KAGAKU KENKYUSHO CO.,LTD. XOMA Ltd. Nippon Chemiphar Co., Ltd. Choongwae Pharma Corp LG Life Sciences, Ltd Metabolex, Inc Wellstat Therapeutics Corporation Opsona Therapeutics Ltd. PLx Pharma Inc. Antibe Therapeutics, Inc. Polaris Group For more information visit http://www.researchandmarkets.com/research/m6..._arthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Benign Prostatic Hyperplasia - Pipeline Review, H2 2013
M2 - Mon Sep 02, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r9fndv/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2013" report to their offering. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Eli Lilly and Company Light Sciences Oncology, Inc. Ipsen S.A. Aphios Corporation Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Dong-A Pharmaceutical Co., Ltd. Addex Pharmaceuticals AEterna Zentaris Inc. IntelGenx Technologies Corp. Kaken Pharmaceutical Co.,Ltd. Karo Bio Nymox Pharmaceutical Corporation Quest PharmaTech Inc. Plethora Solutions Holdings plc Protox Therapeutics Inc. AndroScience Corporation NovaLead Pharma Pvt. Ltd. EndoCeutics, Inc. AmVac AG KAEL-GemVax Ausio Pharmaceuticals, LLC Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/r9..._prostatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/664sjs/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013" report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Scope - A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease). - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Eisai Co., Ltd. Ono Pharmaceutical Co., Ltd. Wockhardt Limited Shire Plc Addex Pharmaceuticals Flamel Technologies S.A. Yuhan Corporation Torrent Pharmaceuticals Limited Ahn-Gook Pharmaceutical Co., Ltd. aRigen Pharmaceuticals, Inc. Cempra Pharmaceuticals, Inc. Vecta Ltd. Sihuan Pharmaceutical Holdings Group Ltd. Reviva Pharmaceuticals Inc. RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/664sjs/reflux About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Women Infertility - Pipeline Review, H2 2013 Report Features Players such as Merck KGaA, EndoCeutics, Inc. and Quatrx Pharmaceutical Company
M2 - Thu Aug 08, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksmjh2/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Women Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women Infertility. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Women Infertility. - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Women Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ASKA Pharmaceutical Co., Ltd - Access Pharmaceuticals, Inc. - Addex Pharmaceuticals - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Camurus AB - Crinetics Pharmaceuticals, Inc. - DONGKOOK Pharmaceutical Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Euroscreen S.A. - Evotec Aktiengesellschaft - Ferring Pharmaceuticals, Inc. - Glycotope GmbH - IBSA Farmaceutici Italia Srl - Intas Pharmaceuticals Ltd. - Isifer AB - JCR Pharmaceuticals Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Neurocrine Biosciences, Inc. - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - Peptron, Inc. - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Repros Therapeutics Inc. - Takeda Pharmaceutical Company Limited - Techpool Bio-Pharma Co., LTD. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - ValiRx Plc - Watson Pharmaceuticals, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/ks...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychosis - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and Clera Inc.
M2 - Tue Aug 06, 12:02PM CDT
Research and Markets (http://www.researchandmarkets.com/research/plc8gk/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Psychosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Psychosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Addex Pharmaceuticals Clera Inc. Evotec Aktiengesellschaft H Lundbeck A/S Newron Pharmaceuticals S.p.A. Reviva Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/plc8gk/psychosi About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obsessive-Compulsive Disorder - Pipeline Review, H1 2013 Report Features Players such as Omeros Corporation and Conformetrix Ltd
M2 - Thu Jun 06, 11:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnsc8t/obsessivecompulsi) has announced the addition of the "Obsessive-Compulsive Disorder - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. S
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 Featuring 16 Major Companies and 29 Drug Profiles
M2 - Thu Apr 18, 6:17AM CDT
Research and Markets has announced the addition of the Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alcohol Addiction - Pipeline Review, H2 2013
M2 - Thu Dec 05, 2:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/gr5s82/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H2 2013" report to their offering. 'Alcohol Addiction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Alcohol Addiction. - A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alcohol Addiction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Eli Lilly and Company Tekmira Pharmaceuticals Corp. Pfizer Inc. Sun Pharmaceutical Industries Limited Addex Pharmaceuticals Curemark, LLC Omeros Corporation Heptares Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/gr..._addiction About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013
M2 - Mon Nov 18, 3:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqp3kf/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013" report to their offering. 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Scope - A snapshot of the global therapeutic scenario for Post-Traumatic Stress Disorder (PTSD). - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Nanotherapeutics, Inc. Neurocrine Biosciences, Inc. Addex Pharmaceuticals Neuralstem, Inc. Catalyst Pharmaceutical Partners, Inc. Humanetics Corporation NeuroNascent, Inc. Azevan Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/zq...ttraumatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dyskinesia - Pipeline Review, H2 2013
M2 - Thu Oct 10, 2:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/893c4b/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H2 2013" report to their offering. 'Dyskinesia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dyskinesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyskinesia. Scope - A snapshot of the global therapeutic scenario for Dyskinesia. - A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dyskinesia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Dyskinesia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned XenoPort, Inc. Novartis AG Cubist Pharmaceuticals, Inc. Addex Pharmaceuticals AVANIR Pharmaceuticals Catalyst Pharmaceutical Partners, Inc. Repligen Corporation Neurim Pharmaceuticals (1991) Ltd. Santhera Pharmaceuticals Holding AG Asubio Pharmaceuticals, Inc. Upsher-Smith Laboratories, Inc. PsychoGenics, Inc. Adamas Pharmaceuticals, Inc. Targacept, Inc. Heptares Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/893c4b/dyskinesia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Endometriosis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9zxrdh/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2013" report to their offering. 'Endometriosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. Scope - A snapshot of the global therapeutic scenario for Endometriosis. - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Endometriosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Euroscreen S.A. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Astellas Pharma Inc. Kissei Pharmaceutical Co., Ltd. Bayer AG Addex Pharmaceuticals Evotec Aktiengesellschaft ValiRx Plc Repros Therapeutics Inc. DONGKOOK Pharmaceutical Co., Ltd. Camurus AB Lipicard Technologies Limited Orphagen Pharmaceuticals, Inc. Quatrx Pharmaceutical Company Peptron, Inc. PregLem SA EndoCeutics, Inc. Isifer AB For more information visit http://www.researchandmarkets.com/research/9z...ometriosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Incontinence - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gnq99s/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2013" report to their offering. 'Urinary Incontinence - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. Scope - A snapshot of the global therapeutic scenario for Urinary Incontinence. - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Cook Medical Incorporated Allergan, Inc. Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation Recordati S.p.A. Addex Pharmaceuticals Evotec Aktiengesellschaft Plethora Solutions Holdings plc Melior Discovery, Inc. Fate Therapeutics, Inc. Celogos Sinil Pharma Ltd. Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/gnq99s/urinary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Spasticity Pipeline Review Report - Latest 2013 Edition
M2 - Wed Sep 04, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrtp7w/spasticity) has announced the addition of the "Spasticity - Pipeline Review, H2 2013" report to their offering. 'Spasticity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. Scope - A snapshot of the global therapeutic scenario for Spasticity. - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spasticity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Spasticity Therapeutics Development - Ipsen S.A. - Novartis AG - Merz GmbH & Co. KGaA - Sun Pharmaceutical Industries Limited - Addex Pharmaceuticals - GW Pharmaceuticals plc - Sanochemia Pharmazeutika AG - Raptor Pharmaceuticals Corp. - Osmotica Pharmaceutical Corp. - Intec Pharma ltd. - Concert Pharmaceuticals, Inc. Drug Profiles - nabiximols - arbaclofen - NGX-426 - tezampanel - abobotulinumtoxinA - onabotulinumtoxinA - BGG-492 - ADX-71441 - SUN-09 - CTP-354 - baclofen ER - onabotulinumtoxinA For more information visit http://www.researchandmarkets.com/research/zrtp7w/spasticity
Gouty Arthritis (Gout) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6xk6h/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2013" report to their offering. 'Gouty Arthritis (Gout) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). Scope - A snapshot of the global therapeutic scenario for Gouty Arthritis (Gout). - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Teijin Pharma Limited Novartis AG Kissei Pharmaceutical Co., Ltd. Addex Pharmaceuticals BioCryst Pharmaceuticals, Inc. SANWA KAGAKU KENKYUSHO CO.,LTD. XOMA Ltd. Nippon Chemiphar Co., Ltd. Choongwae Pharma Corp LG Life Sciences, Ltd Metabolex, Inc Wellstat Therapeutics Corporation Opsona Therapeutics Ltd. PLx Pharma Inc. Antibe Therapeutics, Inc. Polaris Group For more information visit http://www.researchandmarkets.com/research/m6..._arthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Benign Prostatic Hyperplasia - Pipeline Review, H2 2013
M2 - Mon Sep 02, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r9fndv/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2013" report to their offering. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Eli Lilly and Company Light Sciences Oncology, Inc. Ipsen S.A. Aphios Corporation Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Dong-A Pharmaceutical Co., Ltd. Addex Pharmaceuticals AEterna Zentaris Inc. IntelGenx Technologies Corp. Kaken Pharmaceutical Co.,Ltd. Karo Bio Nymox Pharmaceutical Corporation Quest PharmaTech Inc. Plethora Solutions Holdings plc Protox Therapeutics Inc. AndroScience Corporation NovaLead Pharma Pvt. Ltd. EndoCeutics, Inc. AmVac AG KAEL-GemVax Ausio Pharmaceuticals, LLC Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/r9..._prostatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/664sjs/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013" report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Scope - A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease). - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Eisai Co., Ltd. Ono Pharmaceutical Co., Ltd. Wockhardt Limited Shire Plc Addex Pharmaceuticals Flamel Technologies S.A. Yuhan Corporation Torrent Pharmaceuticals Limited Ahn-Gook Pharmaceutical Co., Ltd. aRigen Pharmaceuticals, Inc. Cempra Pharmaceuticals, Inc. Vecta Ltd. Sihuan Pharmaceutical Holdings Group Ltd. Reviva Pharmaceuticals Inc. RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/664sjs/reflux About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Women Infertility - Pipeline Review, H2 2013 Report Features Players such as Merck KGaA, EndoCeutics, Inc. and Quatrx Pharmaceutical Company
M2 - Thu Aug 08, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksmjh2/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Women Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women Infertility. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Women Infertility. - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Women Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ASKA Pharmaceutical Co., Ltd - Access Pharmaceuticals, Inc. - Addex Pharmaceuticals - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Camurus AB - Crinetics Pharmaceuticals, Inc. - DONGKOOK Pharmaceutical Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Euroscreen S.A. - Evotec Aktiengesellschaft - Ferring Pharmaceuticals, Inc. - Glycotope GmbH - IBSA Farmaceutici Italia Srl - Intas Pharmaceuticals Ltd. - Isifer AB - JCR Pharmaceuticals Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Neurocrine Biosciences, Inc. - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - Peptron, Inc. - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Repros Therapeutics Inc. - Takeda Pharmaceutical Company Limited - Techpool Bio-Pharma Co., LTD. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - ValiRx Plc - Watson Pharmaceuticals, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/ks...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psychosis - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and Clera Inc.
M2 - Tue Aug 06, 12:02PM CDT
Research and Markets (http://www.researchandmarkets.com/research/plc8gk/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Psychosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Psychosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Addex Pharmaceuticals Clera Inc. Evotec Aktiengesellschaft H Lundbeck A/S Newron Pharmaceuticals S.p.A. Reviva Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/plc8gk/psychosi About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obsessive-Compulsive Disorder - Pipeline Review, H1 2013 Report Features Players such as Omeros Corporation and Conformetrix Ltd
M2 - Thu Jun 06, 11:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnsc8t/obsessivecompulsi) has announced the addition of the "Obsessive-Compulsive Disorder - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. S
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 Featuring 16 Major Companies and 29 Drug Profiles
M2 - Thu Apr 18, 6:17AM CDT
Research and Markets has announced the addition of the Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of
